Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051280 | 0.91 | CNR2 (0.52) | CNR2RORCSERPINE1CNR1KDM4E | |
| SCHEMBL2038066 | 0.89 | CNR2 (0.56) | CNR2RORCALDH1A1CNR1 | |
| SCHEMBL2036957 | 0.88 | RORC (0.43) | CNR2RORCSERPINE1ALDH1A1KDM4E | |
| SCHEMBL12642925 | 0.87 | CNR2 (0.47) | CNR2RORCSERPINE1ALDH1A1CNR1 | |
| SCHEMBL1985481 | 0.85 | ALDH1A1 (0.46) | CNR2RORCALDH1A1CNR1 | |
| SCHEMBL2037470 | 0.83 | ALDH1A1 (0.42) | CNR2RORCSERPINE1ALDH1A1 | |
| SCHEMBL2037160 | 0.80 | CNR2 (0.56) | CNR2CNR1KDM4E | |
| SCHEMBL12643061 | 0.80 | CNR2 (0.43) | CNR2ALDH1A1 | |
| SCHEMBL2037642 | 0.79 | CNR2 (0.46) | CNR2ALDH1A1CNR1 | |
| SCHEMBL2044112 | 0.78 | HTT (0.46) | CNR2RORCSERPINE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 113/4885RORC 3519/4885SERPINE1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.